Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Athersys, Inc.
  6. Summary
    ATHX   US04744L1061

ATHERSYS, INC.

(ATHX)
  Report
Delayed Quote. Delayed Nasdaq - 01/21 04:00:00 pm
0.7962 USD   -4.53%
01/21Health Care Stocks Decline Pre-Bell Friday
MT
01/21ATHERSYS, INC / NEW : Change in Directors or Principal Officers (form 8-K)
AQ
01/21Athersys Appoints Chief Executive Officer
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
0.8765(c) 0.8211(c) 0.8236(c) 0.834(c) 0.7962(c) Last
1 224 941 787 948 589 651 979 568 1 750 048 Volume
+6.37% -6.32% +0.30% +1.26% -4.53% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,50 M - -
Net income 2021 -84,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,10x
Yield 2021 -
Sales 2022 18,8 M - -
Net income 2022 -97,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,17x
Yield 2022 -
Capitalization 187 M 187 M -
Capi. / Sales 2021 25,0x
Capi. / Sales 2022 9,99x
Nbr of Employees 97
Free-Float 91,8%
More Financials
Company
Athersys, Inc. is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions,... 
More about the company
Ratings of Athersys, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ATHERSYS, INC.
01/21Health Care Stocks Decline Pre-Bell Friday
MT
01/21ATHERSYS, INC / NEW : Change in Directors or Principal Officers (form 8-K)
AQ
01/21Athersys Appoints Chief Executive Officer
MT
01/20Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive ..
BU
01/20Athersys, Inc. Appoints Daniel A. Camardo to the Board of Directors, Effective February..
CI
01/20Athersys, Inc. Appoints Daniel A. Camardo as Chief Executive Officer, Effective Februar..
CI
2021ATHERSYS, INC / NEW : Change in Directors or Principal Officers (form 8-K)
AQ
2021Report of Placebo-Controlled Clinical Trial Evaluating MultiStem« Cell Therapy for Acut..
BU
2021Athersys, Inc. Announces Manuscript Reporting Data from the Company?s Must-ARDS Clinica..
CI
2021BofA Securities Downgrades Athersys to Neutral From Buy; Price Target is $1.25
MT
2021ATHERSYS : REPORTS THIRD QUARTER 2021 RESULTS AND PROVIDES CORPORATE UPDATE - Form 8-K
PU
2021Earnings Flash (ATHX) ATHERSYS Reports Q3 Revenue $4.8M
MT
2021Athersys, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021
CI
2021Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
BU
2021Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
BU
More news
News in other languages on ATHERSYS, INC.
01/21Les actions du secteur de la santé baissent avant la cloche du vendredi
01/21Athersys nomme un directeur général
01/20Athersys, Inc. nomme Daniel A. Camardo au conseil d'administration, à compter du 14 fév..
01/20Athersys, Inc. nomme Daniel A. Camardo au poste de Chief Executive Officer, à compter d..
2021Earnings Flash (ATHX) ATHERSYS annonce un chiffre d'affaires de 4,8 millions de dollars..
More news
Analyst Recommendations on ATHERSYS, INC.
More recommendations
Chart ATHERSYS, INC.
Duration : Period :
Athersys, Inc. Technical Analysis Chart | ATHX | US04744L1061 | MarketScreener
Technical analysis trends ATHERSYS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 0,80 $
Average target price 3,75 $
Spread / Average Target 371%
EPS Revisions
Managers and Directors
William B. J. Lehmann President, Chief Executive & Operating Officer
Ivor MacLeod Chief Financial & Accounting Officer
Ismail Kola Chairman
John J. Harrington Director, Chief Scientific Officer & Executive VP
Rakesh Ramachandran Head-Information Technology & Communications
Sector and Competitors
1st jan.Capi. (M$)
ATHERSYS, INC.-11.79%187
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624